← All trials
NCT01672476
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2012
- Primary completion
- Mar 1, 2013
- Completion date
- Apr 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 293
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Boryung Pharmaceutical CompanyLead sponsor
- Yonsei UniversityOverall official - principal investigator
- Dong-A UniversityCollaborator
- Kangbuk Samsung HospitalCollaborator
- Hanyang UniversityCollaborator
- Yonsei UniversityCollaborator
- Sejong General HospitalCollaborator
- Daegu Catholic UniversityCollaborator
- Korea UniversityCollaborator
- Jeju National UniversityCollaborator
- Konyang UniversityCollaborator
- University of UlsanCollaborator
- Ilsan HospitalCollaborator
- Catholic University of KoreaCollaborator
- Hallym UniversityCollaborator
- Soonchunhyang UniversityCollaborator
- Ewha Womans UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.